

TRADEMARK ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT																	
NATURE OF CONVEYANCE:	ASSIGNS THE ENTIRE INTEREST AND THE GOODWILL																	
CONVEYING PARTY DATA																		
<table border="1"> <thead> <tr> <th>Name</th> <th>Formerly</th> <th>Execution Date</th> <th>Entity Type</th> </tr> </thead> <tbody> <tr> <td>INSPIRATION BIOPHARMACEUTICALS, INC.</td> <td></td> <td>02/15/2013</td> <td>CORPORATION: DELAWARE</td> </tr> <tr> <td>Ipsen Pharma S.A.S.</td> <td></td> <td>02/15/2013</td> <td>CORPORATION: FRANCE</td> </tr> </tbody> </table>				Name	Formerly	Execution Date	Entity Type	INSPIRATION BIOPHARMACEUTICALS, INC.		02/15/2013	CORPORATION: DELAWARE	Ipsen Pharma S.A.S.		02/15/2013	CORPORATION: FRANCE			
Name	Formerly	Execution Date	Entity Type															
INSPIRATION BIOPHARMACEUTICALS, INC.		02/15/2013	CORPORATION: DELAWARE															
Ipsen Pharma S.A.S.		02/15/2013	CORPORATION: FRANCE															
RECEIVING PARTY DATA																		
<table border="1"> <tr> <td>Name:</td> <td>Cangene Corporation</td> </tr> <tr> <td>Street Address:</td> <td>155 Innovation Drive</td> </tr> <tr> <td>City:</td> <td>Winnipeg, MB</td> </tr> <tr> <td>State/Country:</td> <td>CANADA</td> </tr> <tr> <td>Postal Code:</td> <td>R3T 5Y3</td> </tr> <tr> <td>Entity Type:</td> <td>CORPORATION: CANADA</td> </tr> </table>				Name:	Cangene Corporation	Street Address:	155 Innovation Drive	City:	Winnipeg, MB	State/Country:	CANADA	Postal Code:	R3T 5Y3	Entity Type:	CORPORATION: CANADA			
Name:	Cangene Corporation																	
Street Address:	155 Innovation Drive																	
City:	Winnipeg, MB																	
State/Country:	CANADA																	
Postal Code:	R3T 5Y3																	
Entity Type:	CORPORATION: CANADA																	
PROPERTY NUMBERS Total: 4																		
<table border="1"> <thead> <tr> <th>Property Type</th> <th>Number</th> <th>Word Mark</th> </tr> </thead> <tbody> <tr> <td>Serial Number:</td> <td>85220702</td> <td>INOBOXIS</td> </tr> <tr> <td>Serial Number:</td> <td>85220709</td> <td>IXALITY</td> </tr> <tr> <td>Serial Number:</td> <td>85220714</td> <td>IXINITY</td> </tr> <tr> <td>Serial Number:</td> <td>85220704</td> <td>JUBIXYS</td> </tr> </tbody> </table>				Property Type	Number	Word Mark	Serial Number:	85220702	INOBOXIS	Serial Number:	85220709	IXALITY	Serial Number:	85220714	IXINITY	Serial Number:	85220704	JUBIXYS
Property Type	Number	Word Mark																
Serial Number:	85220702	INOBOXIS																
Serial Number:	85220709	IXALITY																
Serial Number:	85220714	IXINITY																
Serial Number:	85220704	JUBIXYS																
CORRESPONDENCE DATA																		
<p>Fax Number: 4087736177</p> <p><i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.</i></p> <p>Phone: 8668774883</p> <p>Email: TrademarksNY@fseip.com</p> <p>Correspondent Name: Fahmi, Sellers, Embert & Davitz</p> <p>Address Line 1: 84 W. Santa Clara Street</p> <p>Address Line 2: Suite 550</p> <p>Address Line 4: San Jose, CALIFORNIA 95113</p>																		

OP \$115.00 85220702

ATTORNEY DOCKET NUMBER:	4328-8001 8003 8030 8034
DOMESTIC REPRESENTATIVE Name: Address Line 1: Address Line 2: Address Line 3: Address Line 4:	
NAME OF SUBMITTER:	Michael A. Davitz
Signature:	/Michael A. Davitz/
Date:	07/19/2013
Total Attachments: 22 source=REDACTED-Assignment-plus co-owned cases[3][1]#page1.tif source=REDACTED-Assignment-plus co-owned cases[3][1]#page2.tif source=REDACTED-Assignment-plus co-owned cases[3][1]#page3.tif source=REDACTED-Assignment-plus co-owned cases[3][1]#page4.tif source=REDACTED-Assignment-plus co-owned cases[3][1]#page5.tif source=REDACTED-Assignment-plus co-owned cases[3][1]#page6.tif source=REDACTED-Assignment-plus co-owned cases[3][1]#page7.tif source=REDACTED-Assignment-plus co-owned cases[3][1]#page8.tif source=REDACTED-Assignment-plus co-owned cases[3][1]#page9.tif source=REDACTED-Assignment-plus co-owned cases[3][1]#page10.tif source=REDACTED-Assignment-plus co-owned cases[3][1]#page11.tif source=REDACTED-Assignment-plus co-owned cases[3][1]#page12.tif source=REDACTED-Assignment-plus co-owned cases[3][1]#page13.tif source=REDACTED-Assignment-plus co-owned cases[3][1]#page14.tif source=REDACTED-Assignment-plus co-owned cases[3][1]#page15.tif source=REDACTED-Assignment-plus co-owned cases[3][1]#page16.tif source=REDACTED-Assignment-plus co-owned cases[3][1]#page17.tif source=REDACTED-Assignment-plus co-owned cases[3][1]#page18.tif source=REDACTED-Assignment-plus co-owned cases[3][1]#page19.tif source=REDACTED-Assignment-plus co-owned cases[3][1]#page20.tif source=REDACTED-Assignment-plus co-owned cases[3][1]#page21.tif source=REDACTED-Assignment-plus co-owned cases[3][1]#page22.tif	

AMENDED AND RESTATED

ASSET PURCHASE AGREEMENT

AMONG

INSPIRATION BIOPHARMACEUTICALS, INC.,

IPSEN PHARMA S.A.S.,

AS SELLERS,

AND

CANGENE CORPORATION,

AS PURCHASER

DATED AS OF FEBRUARY 15, 2013

TABLE OF CONTENTS

	<u>Page</u>
Article I INTERPRETATION	2
Section 1.1 Definitions.....	2
Section 1.2 Other Definitional Provisions..	19
Article II PURCHASE AND SALE OF ASSETS.....	20
Section 2.1 Purchase and Sale of Inspiration Assets..	20
Section 2.2 Purchase and Sale of Ipsen Asset.....	25
Section 2.3 Purchase Price.....	25
Section 2.4 Good Faith Deposit.....	26
Section 2.5 Closing; Closing Date.....	27
Section 2.6 Purchaser Closing Deliverables..	27
Section 2.7 Sellers Closing Deliverables.....	28
Article III REPRESENTATIONS AND WARRANTIES OF INSPIRATION	28
Section 3.1 Organization and Qualification.....	28
Section 3.2 Corporate Authority.....	29
Section 3.3 Approvals.....	29
Section 3.4 Non-Contravention..	29
Section 3.5 Title to Certain Assets.....	29
Section 3.6 Inspiration Contracts.....	30
Section 3.7 Intellectual Property.....	30
Section 3.8 Finders' Fees.....	31
Section 3.9 Litigation.....	31
Section 3.10 Compliance with Laws..	31
Section 3.11 Taxes.....	31
Section 3.12 Labor and Employee Benefits Matters..	32
Section 3.13 Regulatory Matters.....	33
Section 3.14 Sufficiency of Assets..	33
Article IV REPRESENTATIONS AND WARRANTIES OF IPSEN	34
Section 4.1 Organization and Qualification.....	34
Section 4.2 Corporate Authority.....	34
Section 4.3 Approvals.....	34
Section 4.4 Non-Contravention..	34

TABLE OF CONTENTS (continued)

	<u>Page</u>
Section 4.5 No Other Assets.....	35
Section 4.6 Ipsen Assigned Contract..	35
Section 4.7 Finders' Fees.....	35
Section 4.8 Title to Ipsen Assigned Contract.....	35
Article V REPRESENTATIONS AND WARRANTIES OF PURCHASER.....	35
Section 5.1 Organization and Qualification.....	35
Section 5.2 Corporate Authorization..	35
Section 5.3 Consents and Approvals..	36
Section 5.4 Non-Contravention..	36
Section 5.5 Finders' Fees.....	36
Section 5.6 Litigation.....	36
Section 5.7 Financial Statements..	36
Section 5.8 Availability of Funds..	37
Section 5.9 Cure Costs and Adequate Assurance of Future Performance.....	37
Section 5.10 Good Faith..	37
Section 5.11 Purchaser's Acknowledgments; Exclusivity of Representations and Warranties.....	37
Section 5.12 Disclaimer.....	39
Section 5.13 Limitation of Liability.....	39
Article VI COVENANTS AND OTHER AGREEMENTS	40
Section 6.1 Filings; Other Actions; Notification..	40
Section 6.2 Pre-Closing Access to Information.....	43
Section 6.3 Public Announcements..	44
Section 6.4 Further Actions..	44
Section 6.5 Conduct of Business..	44
Section 6.6 Transaction Expenses.....	46
Section 6.7 Confidentiality..	46
Section 6.8 Certain Payments or Instruments Received from Third Parties.....	47
Section 6.9 Joint Contracts..	47
Section 6.10 Insurance Matters.....	48
Section 6.11 Maintenance of Books and Records..	48

TABLE OF CONTENTS (continued)

	<u>Page</u>
Section 6.12 Delivery of Business Information and Tangible Assets..	48
Section 6.13 Delivery of Assignments.....	49
Section 6.14 Milestones.....	49
Section 6.15 Development; Commercialization; Net Sales Payments..	49
Section 6.16 Royalty-Stacking Offset.....	51
Section 6.17 Non-Compete.....	52
Section 6.18 Inspiration Post-Petition Cure Cost Responsibility..	53
Article VII TAX MATTERS	53
Section 7.1 Transfer Taxes..	53
Section 7.2 Withholding Taxes.....	53
Section 7.3 Distribution Agent..	54
Section 7.4 Proration of Certain Taxes.....	54
Section 7.5 Survival of Article VII.....	55
Article VIII EMPLOYMENT MATTERS	55
Section 8.1 Employment Obligations..	55
Section 8.2 Other Employee Matters.....	62
Article IX CONDITIONS TO THE CLOSING	63
Section 9.1 Conditions to Each Party's Obligation..	63
Section 9.2 Conditions to Sellers' Obligation.....	63
Section 9.3 Conditions to Purchaser's Obligation..	64
Article X TERMINATION.....	65
Section 10.1 Termination.....	65
Section 10.2 Effects of Termination..	66
Article XI MISCELLANEOUS	66
<u>Section 11.1 Survival of Representations and Warranties or Covenants.....</u>	<u>66</u>
<u>Section 11.2 Indemnification.....</u>	<u>66</u>
Section 11.3 Waivers..	68
Section 11.4 No Third-Party Beneficiaries.....	68
Section 11.5 Consent to Amendments; Waivers.....	69
Section 11.6 Successors and Assigns.....	69
Section 11.7 Governing Law; Submission to Jurisdiction; Waiver of Jury Trial.....	69

TABLE OF CONTENTS (continued)

	<u>Page</u>
Section 11.8 Notices..	70
Section 11.9 Exhibits; Disclosure Schedules.....	72
Section 11.10 Counterparts.....	73
Section 11.11 Severability..	73
Section 11.12 Entire Agreement.....	73
Section 11.13 Remedies.....	73
Section 11.14 Sellers' Representative.....	74
Section 11.15 Bulk Sales Laws.....	75
Section 11.16 Joint Negotiation.....	75
Section 11.17 Multi-Party Agreement..	75
Section 11.18 Headings..	75

LIST OF SCHEDULES

SCHEDULE 1.1(a)	Employees
SCHEDULE 1.1(b)	Inspiration Assigned Contracts
SCHEDULE 1.1(c)	Inspiration Contracts
SCHEDULE 1.1(d)(i)	Inspiration Transferred Intellectual Property (Trademarks)
SCHEDULE 1.1(d)(ii)	Inspiration Transferred Intellectual Property (Patents)
SCHEDULE 1.1(e)	Joint Contracts
SCHEDULE 1.1(f)	Inspiration Persons with Knowledge
SCHEDULE 1.1(g)	Owned Inventory
SCHEDULE 1.1(h)	Required Approvals
SCHEDULE 2.1(a)(x)	IND, CTA and Marketing Applications
SCHEDULE 2.1(b)(v)	Inspiration Excluded Assets (Causes of Action)
SCHEDULE 2.1(b)(viii)	Inspiration Excluded Assets
SCHEDULE 2.1(b)(xi)	Inspiration Excluded Assets (Real Property Leases)
SCHEDULE 8.1(a)(iv)	Transition Services Employees

DISCLOSURE SCHEDULES

PURCHASER DISCLOSURE SCHEDULE:

Section 1.1	Purchaser Persons with Knowledge
Section 5.3	Consents and Approvals

INSPIRATION DISCLOSURE SCHEDULE:

Section 3.3	Consents and Approvals
Section 3.6	Inspiration Assigned Contracts
Section 3.7(a)(i)	Inspiration Registered IP
Section 3.7(a)(ii)	License Grant to Third Parties
Section 3.7(a)(iii)	Inspiration Licensed Intellectual Property Rights
Section 3.7(d)	Oppositions
Section 3.9	Litigation
Section 3.13(b)	Clinical Trials

IPSEN DISCLOSURE SCHEDULE:

None

AMENDED AND RESTATED ASSET PURCHASE AGREEMENT

This Amended and Restated Asset Purchase Agreement, dated February 15, 2013, is made among Inspiration Biopharmaceuticals, Inc., a Delaware corporation (“Inspiration”), Ipsen Pharma S.A.S., a company incorporated under the laws of France (“Ipsen,” and together with Inspiration, each, a “Seller” and collectively, “Sellers”), and Cangene Corporation, an Ontario corporation (“Purchaser,” and together with Sellers, each, a “Party” and collectively, the “Parties”).

WITNESSETH:

WHEREAS, on October 30, 2012, Inspiration filed a petition under Chapter 11 of the Bankruptcy Code, 11 U.S.C. § 101 et seq. (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Massachusetts commencing Chapter 11 bankruptcy case number 12-18687-WCH (the “Bankruptcy Case”);

WHEREAS, Inspiration is a biopharmaceutical company engaged in the Development of the FIX Product, the other Products, as well as other product candidates for the treatment of hemophilia (the “Business”);

WHEREAS, Ipsen is a global specialty-driven pharmaceutical company and has certain co-development and commercialization rights in the FIX Product;

WHEREAS, Inspiration, Ipsen and Purchaser entered into that certain Asset Purchase Agreement, dated as of February 5, 2013 (the “Signing Date”) and that certain Amendment to the Asset Purchase Agreement, dated as of February 5, 2013 (collectively, the “Original Asset Purchase Agreement”), pursuant to which (i) Inspiration on behalf of itself and its relevant Affiliates, agreed to sell and transfer to Purchaser, and Purchaser, on behalf of itself and its relevant Affiliates, agreed to purchase and assume from Inspiration, pursuant to Sections 363 and 365 of the Bankruptcy Code, the Bidding Procedures, the terms and conditions of the Original Asset Purchase Agreement and the approval of the Bankruptcy Court, substantially all of the assets of Inspiration and its Affiliates primarily relating to the FIX Product and the other Products, and certain of the liabilities of Inspiration, and (ii) Ipsen, on behalf of itself and its relevant Affiliates, agreed to sell and transfer to Purchaser, and Purchaser, on behalf of itself and its relevant Affiliates, agreed to purchase and assume from Ipsen, pursuant to the Bidding Procedures and the terms and conditions of the Original Asset Purchase Agreement and the approval of the Bankruptcy Court, all of Ipsen’s and its Affiliates’ rights to the FIX Product and certain liabilities related thereto;


WHEREAS, in accordance with the Bidding Procedures Order, Purchaser has delivered to Sellers the Good Faith Deposit;

WHEREAS, concurrently with or subsequent to the Closing, the Parties intend to enter into, or to cause to be entered into, the Ancillary Agreements; and

WHEREAS, concurrently with the Closing, the Parties consider it advisable to amend and restate the Original Asset Purchase Agreement in its entirety.

IN WITNESS WHEREOF, the undersigned have duly executed this Amended and Restated Asset Purchase Agreement as of the date first written above.

CANGENE CORPORATION

By: 
Name: Francis J. St. Hilaire
Title: Vice President, General Counsel &
Secretary

INSPIRATION BIOPHARMACEUTICALS, INC.

By: _____
Name:
Title:

IPSEN PHARMA S.A.S.

By: _____
Name:
Title:

[Signature Page to the Amended & Restated Asset Purchase Agreement]


TRADEMARK
REEL: 005074 FRAME: 0373

IN WITNESS WHEREOF, the undersigned have duly executed this Amended and Restated Asset Purchase Agreement as of the date first written above.

CANGENE CORPORATION

By: _____
Name: Francis J. St. Hilaire
Title: Vice President, General Counsel &
Secretary

INSPIRATION BIOPHARMACEUTICALS, INC.

By:  _____
Name: John P. Butler
Title: CEO

IPSEN PHARMA S.A.S.

By: _____
Name:
Title:

IN WITNESS WHEREOF, the undersigned have duly executed this Amended and Restated Asset Purchase Agreement as of the date first written above.


CANGENE CORPORATION

By: _____
Name:
Title:

INSPIRATION BIOPHARMACEUTICALS, INC.

By: _____
Name:
Title:

IPSEN PHARMA S.A.S.

By:  _____
Name: Nathalie Joannes
Title: Executive Vice President, General Counsel

[Signature Page to the Amended & Restated Asset Purchase Agreement]

SCHEDULE 1.1(d)(i) – Inspiration Transferred Intellectual Property: Trademarks

INOBOXIS	Ref: 4004-311835	CTM
Inspiration Biopharmaceuticals, Inc.		
Reg No : 009671215	Jun 27 2011	Registered
App No : 009671215	Jan 19 2011	
RENEWAL DUE:	Jan 19 2021	

Class	5
Goods	Pharmaceutical preparations for the treatment of hemophilia.

INOBOXIS	Ref: 4000-311835	United States of America
Inspiration Biopharmaceuticals, Inc.		
Reg No :		Pending
App No : 85220702	Jan 19 2011	
RENEWAL DUE:		

Class	5
Goods	Pharmaceutical preparations for the treatment of hemophilia

IXALITY	Ref: 4005-311835	CTM
Inspiration Biopharmaceuticals, Inc.		
Reg No : 009671231	Jun 27 2011	Registered
App No : 009671231	Jan 19 2011	
RENEWAL DUE:	Jan 19 2021	

Class	5
Goods	Pharmaceutical preparations for the treatment of hemophilia.

IXALITY	Ref: 4001-311835	United States of America
Inspiration Biopharmaceuticals, Inc.		
Reg No :		Pending
App No : 85220709	Jan 19 2011	
RENEWAL DUE:		

Class	5
Goods	Pharmaceutical preparations for the treatment of hemophilia

IXinity	Ref: 4015-311835	Argentina
Inspiration Biopharmaceuticals, Inc.		
Reg No :		Pending
App No : 3165116	May 17 2012	
RENEWAL DUE:		

Class	5
Goods	Pharmaceutical preparations

IXINITY	Ref: 4014-311835	Australia
Inspiration Biopharmaceuticals, Inc.		
Reg No :		Pending
App No : 1480170	Mar 14 2012	
RENEWAL DUE:		

Class	5
--------------	----------

Goods	Pharmaceutical preparations
--------------	------------------------------------

IXINITY	Ref: 4013-311835	Brazil
Inspiration Biopharmaceuticals, Inc.		
Reg No :		Pending
App No : 904637328	Mar 23 2012	
RENEWAL DUE:		

Class	5
Goods	Pharmaceutical preparations

IXINITY	Ref: 4017-311835	Canada
Inspiration Biopharmaceuticals, Inc.		
Reg No :		Pending
App No : 1568455	Mar 13 2012	
RENEWAL DUE:		

Class	5
Goods	(1) Pharmaceutical preparations.

IXinity	Ref: 4027-311835	Chile
Inspiration Biopharmaceuticals, Inc.		
Reg No :		Pending
App No : 999711	Mar 23 2012	
RENEWAL DUE:		

Class	5
Goods	Pharmaceutical preparations

IXinity	Ref: 4016-311835	China
Inspiration Biopharmaceuticals, Inc.		
Reg No :		Pending
App No : 10645298	Mar 20 2012	
RENEWAL DUE:		

Class	5
Goods	Pharmaceutical preparations

IXinity	Ref: 4029-311835	Colombia
Inspiration Biopharmaceuticals, Inc.		
Reg No :		Pending
App No : 12079796	May 15 2012	
RENEWAL DUE:		

Class	5
Goods	Pharmaceutical preparations for the treatment of bleeding disorders

IXINITY	Ref: 4006-311835	CTM
Inspiration Biopharmaceuticals, Inc.		
Reg No : 009671249	Jun 27 2011	Registered
App No : 009671249	Jan 19 2011	
RENEWAL DUE:	Jan 19 2021	

Class	5
Goods	Pharmaceutical preparations for the treatment of hemophilia.

IXINITY	Ref: 4018-311835	India
Inspiration Biopharmaceuticals, Inc.		
Reg No :		Pending
App No : 2299289	Mar 14 2012	
RENEWAL DUE:		

Class	5
Goods	Pharmaceutical preparations

IXinity	Ref: 4032-311835	Indonesia
Inspiration Biopharmaceuticals, Inc.		
Reg No :		Pending
App No : D002012013996	Mar 27 2012	
RENEWAL DUE:		

Class	5
Goods	Pharmaceutical preparations

IXINITY	Ref: 4012-311835	Israel
Inspiration Biopharmaceuticals, Inc.		
Reg No :		Pending
App No : 245198	Mar 14 2012	
RENEWAL DUE:		

Class	5
Goods	Pharmaceutical preparations

IXinity	Ref: 4011-311835	Japan
Inspiration Biopharmaceuticals, Inc.		
Reg No :		Pending
App No : 2012-019936	Mar 15 2012	
RENEWAL DUE:		

Class	5
Goods	Pharmaceutical preparations

IXinity	Ref: 4035-311835	Kazakhstan
Inspiration Biopharmaceuticals, Inc.		
Reg No :		Pending
App No : 57589	Mar 26 2012	
RENEWAL DUE:		

Class	5
Goods	Pharmaceutical preparations

IXinity	Ref: 4010-311835	Korea South
Inspiration Biopharmaceuticals, Inc.		
Reg No :		Pending
App No : 4020120020248	Mar 27 2012	
RENEWAL DUE:		

Class	5
--------------	----------

Goods	Pharmaceutical preparations
--------------	------------------------------------

IXinity	Ref: 4031-311835	Kuwait
Inspiration Biopharmaceuticals, Inc.		
Reg No :		Pending
App No : 128765	Mar 27 2012	
RENEWAL DUE:		

Class	5
Goods	Pharmaceutical preparations

IXINITY	Ref: 4019-311835	Mexico
Inspiration Biopharmaceuticals, Inc.		
Reg No : 1302878	Aug 9 2012	Registered
App No : 1258399	Mar 15 2012	
RENEWAL DUE:	Mar 15 2022	

Class	5
Goods	Pharmaceutical preparations

IXinity	Ref: 4020-311835	New Zealand
Inspiration Biopharmaceuticals, Inc.		
Reg No : 955543	Sep 18 2012	Registered
App No : 955543	Mar 14 2012	
RENEWAL DUE:	Mar 14 2022	

Class	5
Goods	Pharmaceutical preparations

IXINITY	Ref: 4021-311835	Norway
Inspiration Biopharmaceuticals, Inc.		
Reg No : 266290	Jul 6 2012	Registered
App No : 201202805	Mar 14 2012	
RENEWAL DUE:	Mar 14 2022	

Class	5
Goods	Pharmaceutical preparations

Class	42
Goods	Pharmaceutical research and development services

Class	44
Goods	Medical services; medical treatment; health services; information relating to medical services, medical treatment and pharmaceutical preparations.

IXINITY	Ref: 4028-311835	Peru
Inspiration Biopharmaceuticals, Inc.		
Reg No : 190646	Aug 15 2012	Registered
App No : 487424	Mar 21 2012	
RENEWAL DUE:	Aug 15 2022	

Class	5
Goods	Pharmaceutical preparations

IXinity	Ref: 4022-311835	Russian Federation
Inspiration Biopharmaceuticals, Inc.		
Reg No :		Pending

App No : 2012707588
RENEWAL DUE:

Mar 15 2012

Class	5
Goods	Pharmaceutical preparations

IXinity	Ref: 4030-311835	Saudi Arabia
Inspiration Biopharmaceuticals, Inc.		
Reg No :		Pending
App No : 180225	Mar 27 2012	
RENEWAL DUE:		

Class	5
Goods	Pharmaceutical preparations

IXinity	Ref: 4024-311835	South Africa
Inspiration Biopharmaceuticals, Inc.		
Reg No :		Pending
App No : 201207095	Mar 19 2012	
RENEWAL DUE:		

Class	5
Goods	Pharmaceutical preparations

IXinity	Ref: 4025-311835	Switzerland
Inspiration Biopharmaceuticals, Inc.		
Reg No : 627391	Mar 22 2012	Registered
App No : 627391	Mar 14 2012	
RENEWAL DUE:	Mar 14 2022	

Class	5
Goods	Pharmaceutical preparations

IXinity	Ref: 4026-311835	Taiwan
Inspiration Biopharmaceuticals, Inc.		
Reg No :		Pending
App No : 101017402	Apr 2 2012	
RENEWAL DUE:		

Class	5
Goods	Pharmaceutical preparations

IXinity	Ref: 4034-311835	Thailand
Inspiration Biopharmaceuticals, Inc.		
Reg No :		Pending
App No : 841121	Mar 27 2012	
RENEWAL DUE:		

Class	5
Goods	pharmaceutical preparations for the treatment of hemophilia

IXINITY	Ref: 4036-311835	Ukraine
Inspiration Biopharmaceuticals, Inc.		
Reg No :		Pending
App No : m201204919	Mar 22 2012	
RENEWAL DUE:		

Class	5
Goods	Pharmaceutical preparations

IXINITY	Ref: 4002-311835	United States of America
Inspiration Biopharmaceuticals, Inc.		
Reg No :		Pending
App No : 85220714	Jan 19 2011	
RENEWAL DUE:		

Class	5
Goods	Pharmaceutical preparations for the treatment of hemophilia

IXinity	Ref: 4033-311835	Vietnam
Inspiration Biopharmaceuticals, Inc.		
Reg No :		Pending
App No : 4201205679	Mar 27 2012	
RENEWAL DUE:		

Class	5
Goods	Pharmaceutical preparations

IXinity / IXINITY (series of 2)	Ref: 4023-311835	Singapore
Inspiration Biopharmaceuticals, Inc.		
Reg No :		Pending
App No : T1203520H	Mar 15 2012	
RENEWAL DUE:		

Class	5
Goods	Pharmaceutical preparations

JUBIXYS	Ref: 4007-311835	CTM
Inspiration Biopharmaceuticals, Inc.		
Reg No : 009671223	Jun 27 2011	Registered
App No : 009671223	Jan 19 2011	
RENEWAL DUE:	Jan 19 2021	

Class	5
Goods	Pharmaceutical preparations for the treatment of hemophilia.

JUBIXYS	Ref: 4003-311835	United States of America
Inspiration Biopharmaceuticals, Inc.		
Reg No :		Pending
App No : 85220704	Jan 19 2011	
RENEWAL DUE:		

Class	5
Goods	Pharmaceutical preparations for the treatment of hemophilia

SCHEDULE 1.1(d)(ii) – Inspiration Transferred Intellectual Property: Patents**FACTOR VIII (HUMAN)****METHOD OF PRODUCING BIOLOGICALLY ACTIVE VITAMIN K DEPENDENT PROTEINS BY RECOMBINANT METHODS (UNC and INSPIRATION co-owned)**

Application No. / Patent No.	Country	Filing Date	NOTES/STATUS
11/643,563 (co-owned with UNC)	US	12/21/2006	Abandoned
60/752,642	US Prov	12/21/2005	Closed
PCT/US2006/048954	PCT	12/21/2006	Closed
2006331501	AU	12/21/2006	Pending Acceptance 8/15/2013
6848864.2	EP	12/21/2006	Published
11157194.9	EP	12/21/2006	Published
2008-547588	JP	12/21/2006	Pending
12104533.2	HK	5/9/2012	Published
2,633,661	CA	12/21/2006	Pending
13/681,021	US	11/19/2012	Pending

PROCESS FOR IMPROVING FVIII PRODUCTION (U of Michigan and Inspiration co-owned)

Application No. / Patent No.	Country	Filing Date	NOTES/STATUS
11/771,400 US2008/0070251	US	6/29/2007	ABANDONED
60/818,177	US	6/30/2006	EXPIRED
PCT/US07/072506	PCT	6/29/2007	nationalized
12/758,457	US	4/12/2010	RCE filed 6/13/2012 Pending
12/252,024 US2009/0203077	US CIP	10/15/2008	PENDING and published
2007269233	AU	6/29/2007	GRANTED
7812491.4	EP	6/29/2007	PENDING
12164874.5	EP DIV		Pending
2656558	CA	6/29/2007	PENDING
2009518576	JP	6/29/2007	PENDING-published
13/153,040	US	6/3/2011	PENDING
PCT/US2012/040376	WO	6/1/2012	Pending

FACTOR VIIa**METHOD OF PRODUCING RECOMBINANT VITAMIN K DEPENDENT PROTEINS
(Inspiration owned)**

Application No. / Patent No.	Country	Filing Date	NOTES/STATUS
61/256,802	US PROV	10/30/2009	EXPIRED
PCT/US2010/054581	PCT	10/28/2010	PUBLISHED Nationalized
13/459,743	US	4/30/2012	Published
10827499.4	EP	10/28/2010 (PCT date)	Published
2012-537082	JP	10/28/2010 (PCT date)	Pending

**Recombinant Vitamin K Dependent Proteins with High Sialic Acid Content And Methods
of Preparing Same (Inspiration owned)**

Application No. / Patent No.	Country	Filing Date	NOTES/STATUS
12/597,456	US	10/23/2009	PUBLISHED
60/914,281	US PROV	4/26/2007	CLOSED
60/917,271	US PROV	5/10/2007	CLOSED
PCT/US2008/061822	PCT	4/28/2008	EXPIRED
2008245524	AU	4/28/2008	Pending
2683423	CA	4/28/2008	Pending
8747060.5	EP	4/28/2008	Pending
2010-506563	JP	4/28/2008	PUBLISHED-pending
12170422.5	EP	4/28/2012	Pending-published

**Method Of Producing Biologically Active Vitamin K Dependent Proteins By Recombinant Methods
(UNC and INSPIRATION co-owned)**

Application No. / Patent No.	Country	Filing Date	NOTES/STATUS
11/643,563 (co-owned with UNC)	US	12/21/2006	ABANDONED
60/752,642	US Prov	12/21/2005	EXPIRED
PCT/US2006/048954	WO	12/21/2006	EXPIRED
2006331501	AU	12/21/2006	PENDING
6848864.2	EP	12/21/2006	PENDING
11157194.9	EP	12/21/2006	PENDING
2008-547588	JP	12/21/2006	PENDING
12104533.2	HK	5/9/2012	PENDING
2,633,661	CA	12/21/2006	PENDING
13/681,021	US	11/19/2012	PENDING

FACTOR IX**HUMAN FACTOR IX VARIANTS WITH AN EXTENDED HALF LIFE
(UNC and INSPIRATION co-owned)**

Application No. / Patent No.	Country	Filing Date	NOTES/STATUS
60/999,035	US PROV	10/15/2007	EXPIRED
12/734,181 2011/0154516	US	4/15/2010	PUBLISHED 06/23/2011
PCT/US08/011754 WO09051717	PCT	10/15/2008	EXPIRED
2008311793	AU	10/15/2008	N/A
2702363	CA	10/15/2008	N/A
2008801222149.00	CN	10/15/2008	N/A
8839270.9	EP	10/15/2008	N/A
1739KOLNP2010	IN	10/15/2008	N/A
2010529936	JP	10/15/2008	N/A

**METHOD OF PRODUCING RECOMBINANT VITAMIN K DEPENDENT PROTEINS
(INSPIRATION owned)**

Application No. / Patent No.	Country	Filing Date	NOTES/STATUS
61/256,802	US PROV	10/30/2009	EXPIRED
PCT/US2010/054581	PCT	10/28/2010	PUBLISHED Nationalized
13/459,743	US	4/30/2012	Published
10827499.4	EP	10/28/2010 (PCT date)	Published
2012-537082	JP	10/28/2010 (PCT date)	Pending

STABILIZED FACTOR IX FORMULATIONS CONTAINING TREHALOSE

(Inspiration Owned)

Application No. / Patent No.	Country	Filing Date	NOTES/STATUS
12/744,017	US	5/28/2010	PUBLISHED
61/016,230	US PROV	12/21/2007	CLOSED
PCT/US2008/087031 (WO2009/082648)	PCT	12/16/2008	CLOSED
2008340304	AU	12/16/2008	Pending
PI0821591-0	BR	12/16/2008	PENDING
2707032	CA	12/16/2008	Pending
200880122207.90	CN	12/16/2008	Pending
8864646.8	EP	12/16/2008	PUBLISHED
1530/MUMNP/2010	IN	12/16/2008	Pending-published
2010-539710	JP	12/16/2008	Pending-PUBLISHED
2010122379	RU	12/16/2008	Pending

METHOD OF PRODUCING BIOLOGICALLY ACTIVE VITAMIN K DEPENDENT PROTEINS BY RECOMBINANT METHODS

(UNC and INSPIRATION co-owned)

Application No. / Patent No.	Country	Filing Date	NOTES/STATUS
11/643,563	US	12/21/2006	Abandoned
60/752,642	US Prov	12/21/2005	Closed
PCT/US2006/048954	PCT	12/21/2006	Closed
2006331501	AU	12/21/2006	Pending Acceptance 8/15/2013
6848864.2	EP	12/21/2006	Published
11157194.9	EP	12/21/2006	Published
2008-547588	JP	12/21/2006	Pending
12104533.2	HK	5/9/2012	Published
2,633,661	CA	12/21/2006	Pending
13/681,021	US	11/19/2012	Pending

**RECOMBINANT VITAMIN K DEPENDENT PROTEINS WITH HIGH SIALIC ACID CONTENT
AND METHODS OF PREPARING SAME**

(INSPIRATION owned)

Application No. / Patent No.	Country	Filing Date	NOTES/STATUS
12/597,456	US	10/23/2009	PUBLISHED
60/914,281	US PROV	4/26/2007	CLOSED
60/917,271	US Prov	5/10/2007	EXPIRED
PCT/US2008/061822	PCT	4/28/2008	EXPIRED
2008245524	AU	4/28/2008	Pending
2683423	CA	4/28/2008	Pending
8747060.5	EP	4/28/2008	Pending
2010-506563	JP	4/28/2008	PUBLISHED-pending
12170422.5	EP	4/28/2012	Pending-published